Midkine News 2020, page-11

Midkine is a tumor cell survival factor that displays metastatic and therapeutic resistance functions in uveal melanoma

https://iovs.arvojournals.org/article.aspx?articleid=2768349

Results : We found a significant correlation between midkine expression in primary uveal melanoma and overall survival. Patients with high midkine expression displayed only a 20% 5-year survival, whereas patients with low midkine levels displayed a 90% survival rate. (...)

Conclusions : Midkine is identified as a tumor cell survival factor that drives metastasis and therapeutic resistance, and could be exploited as a biomarker as well as therapeutic target in uveal melanoma.